What is the share price of Cipla (CIPLA)?

Cipla last traded at ₹1,418.70 (-0.8% on the day), as of 7/17/2026. For education only, not investment advice.

What is Cipla's revenue?

Cipla reported revenue of ₹28,163 Cr for FY2026, with net profit of ₹3,879 Cr.

Cipla

CIPLA · NSE · Pharma · India

₹1,418.70-0.8%

Delayed · as reported by Yahoo Finance · as of Jul 17, 2026, 10:00 AM

Snapshot

TickerCIPLA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees31,369

HeadquartersMumbai, India

Market cap₹1,14,609 Cr

P/B3.3

Volume6.07L

Websitewww.cipla.com

Filings tracked9

About Cipla — read

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters31.1%
Institutions44.0%
Public & other24.8%

238 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

₹1,165.7052-wk range₹1,673.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Market cap

₹1,14,609 Cr

Day change

-0.8%

Fwd P/E

22.3

P/B

3.3

Div yield

0.92%

Beta

0.11

Revenue (FY2026)

₹28,163 Cr

Net margin

13.8%

Revenue CAGR (3y)

+7.4%

Profit CAGR (3y)

+11.5%

Net profit (FY2026)

₹3,879 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CIPLA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jun 22, 2026+4.7%
Cipla shares rose over 4% after Citi maintained its Buy rating and placed the stock on a 90-day Positive Catalyst Watch, highlighting multiple upcoming growth triggers.
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about CIPLA

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹28,163 Cr	₹3,879 Cr	13.8%
FY2025	₹27,548 Cr	₹5,273 Cr	19.1%
FY2024	₹25,774 Cr	₹4,122 Cr	16.0%
FY2023	₹22,753 Cr	₹2,802 Cr	12.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹6,541 Cr	₹555 Cr	8.5%
2025Q4	₹7,074 Cr	₹676 Cr	9.6%
2025Q3	₹7,589 Cr	₹1,351 Cr	17.8%
2025Q2	₹6,957 Cr	₹1,298 Cr	18.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Please find enclosed disclosure on USFDA inspection at InvaGen manufacturing facility in Long Island, NY, USA
BSE7/18/2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed disclosure on ESG Rating.
BSE7/12/2026
Corrigendum To The Intimation Dated 3Rd July, 2026 Regarding 'Transcript Of The 90Th Annual General Meeting'
Please find enclosed transcript.
BSE7/4/2026
Transcript Of The 90Th Annual General Meeting
Please find enclosed transcript.
BSE7/3/2026
Appointment of Statutory Auditor/s
Please find enclosed intimation
BSE6/25/2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find enclosed Proceedings of AGM
BSE6/25/2026material
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Details of voting results of the 90th Annual General Meeting of the Company and Scrutiniser''s report
BSE6/25/2026material
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached disclosure on ESG Rating.
BSE6/25/2026
Board Meeting Intimation for The Quarter Ended 30Th June, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....
BSE6/24/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.